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ABSTRACT
Summary: Cancer is an evolutionary disease, and there is increasing interest
in applying tools from evolutionary biology to understand cancer progression.
Restriction-site associated DNA sequencing (RADseq) was developed for the field
of evolutionary genetics to study adaptation and identify evolutionary relationships
among populations. Here we apply RADseq to study tumor evolution, which allows for
unbiased sampling of any desired frequency of the genome, overcoming the selection
bias and cost limitations inherent to exome or whole-genome sequencing. We apply
RADseq to both human pancreatic cancer and zebrafish melanoma samples. Using
either a low-frequency (SbfI, 0.4% of the genome) or high-frequency (NsiI, 6-9% of
the genome) cutter, we successfully identify single nucleotide substitutions and copy
number alterations in tumors, which can be augmented by performing RADseq on
sublineages within the tumor. We are able to infer phylogenetic relationships between
primary tumors and metastases. These same methods can be used to identify somatic
mosaicism in seemingly normal, non-cancerous tissues. Evolutionary studies of cancer
that focus on rates of tumor evolution and evolutionary relationships among tumor
lineages will benefit from the flexibility and efficiency of restriction-site associated
DNA sequencing.

INTRODUCTION

the generation and maintenance of tumor diversity are
of particular interest to those seeking to understand
disease progression and therapeutic resistance of
advanced cancers. A multidisciplinary approach has been
increasingly applied to problems of clonal evolution
in cancer [2-6]. Theory and tools from evolutionary
biology have been applied to the field of cancer biology
to understand the rates of accumulation of mutations in
cellular lineages [5, 7], spatial and temporal patterns of
intratumor heterogeneity [8-10], the timing and order of
metastatic progression [11-14], and optimal strategies
for therapeutic dosing and schedules [15-17]. However,

The characterization of cancer as an evolutionary
process was reviewed by Peter Nowell four decades
ago. He hypothesized a stepwise progression of acquired
variation and natural selection to explain the emergence
and increasing aggressiveness of tumors [1]. Since then,
data from cancer genomics, multi-region sequencing,
and single-cell sequencing have provided new insight
into the complex clonal evolution of tumors and the
extensive genetic heterogeneity present within and
between cancer patients. The mechanisms underlying
www.impactjournals.com/oncotarget
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a large disciplinary divide still exists between cancer
biology and evolutionary biology, and potentially useful
theoretical and experimental tools have yet to be applied
across disciplines.
Restriction-site associated DNA sequencing
(RADSeq) was initially developed for studies of
evolutionary genetics and has proven to be a powerful
tool in this field. This method has been largely overlooked
in cancer biology, which instead relies almost exclusively
on whole-genome sequencing and exome sequencing to
discover and quantify genetic variation in tumors (see
Figure 1 for a comparison of the three methods). Like
exome sequencing, RADSeq is a reduced-representation
sequencing approach that targets a subset of the genome.
However, instead of targeting exonic regions for
sequencing, the RADseq protocol targets regions of the
genome flanking restriction enzyme cut sites. Several
variations of RADseq have been described [18-24]. In
brief, high quality genomic DNA is first digested with a
restriction enzyme. Then, sequencing adapters (doublestranded oligos compatible with a next generation
sequencing platform) are ligated onto the characteristic
sticky ends generated by the restriction enzyme digestion.
The highly-specific ligation of sequencing adapters to
digested cut sites allows for the targeted sequencing of
regions flanking these positions, therefore no capture step
is required. Barcode sequences can also be included in
the adapter oligos to allow for multiplexed sequencing of
multiple samples in the same sequencing lane.
RADseq is a highly flexible approach because the
proportion of the genome targeted for sequencing can
be controlled through the choice of restriction enzyme.
Common cutters (typically enzymes with a shorter
recognition sequence,) will target a higher percentage of
genome for sequencing than rare cutters. This means that
common cutters can be used for questions that require
more sequence information per genome, for example
to distinguish between recently-diverged populations
(e.g. primary tumors vs. metastases) or tumors with low
mutation rates/burdens (e.g. pediatric tumors). Rare cutters
can be selected for research questions that call for fewer
sites per genome and a greater depth of sequencing per
site (e.g. heterogeneity questions), or benefit from a large
number of samples (e.g. many tumor sites or patients).
RADseq differs from whole-exome sequencing in
that it does not specifically target functional regions of
the genome. Restriction cut sites occur throughout the
genome, largely without bias, and thus the sequenced
regions will represent coding DNA as well as many
intergenic and other non-coding sites where non-coding
RNAs might be transcribed as well. This important
distinction means that RADseq will likely not be the most
efficient method to identify driver mutations and protein
changes responsible for the cancer phenotype. However,
RADseq does have the potential to be a more useful tool
than exome sequencing to study tumor phylogenetics
www.impactjournals.com/oncotarget

and intrinsic mutation rates, for which neutrally evolving
sites provide the most robust information [25-27]. These
differing strengths make whole-exome sequencing and
RADseq complimentary methods for a variety of cancer
biology questions. Here we test the utility of RADseq
for cancer genomics by applying RADseq to a zebrafish
model of melanoma and to human pancreatic tumors.

RESULTS
Transgenic zebrafish model of melanoma
Performance
We applied RADseq to a zebrafish model of
melanoma to identify mutations from matched pairs
of tumor and normal tissue (Figure 2A). Transgenic
p53-deficient zebrafish expressing the mutant form of
human BRAF(V600E) in melanocytes spontaneously
develop melanoma at 4-12 months of age ;
Tg(mitfa:BRAF(V600E)); p53-/- [28, 29]. We dissected
melanoma tumors and normal skin from three adult fish
and used the restriction enzyme SbfI (a rare cutter, with
an 8bp recognition sequence) to prepare RADseq libraries
for sequencing on the Illumina platform (HiSeq2500).
In silico analysis using the zebrafish reference genome
[30] predicts 30,667 SbfI restriction enzyme cut sites
in the genome. Because the recognition sequence of the
restriction enzyme is palindromic, each occurrence of
the recognition sequence results in two cuts, one on each
opposing DNA strand. This generates sequence coverage
in both directions from the cut site [22, 23]. We sequenced
100bp flanking both sides of each cut site in the 1.4Gb
genome, resulting in representation of approximately 0.4%
of the genome. The average depth of coverage for these
loci was ~350x, and coverage was even across loci (358x
mean, 337x median).
After filtering reads for quality, we found that 91.5%
of sequencing reads successfully mapped to the zebrafish
reference genome and 94.2% of these reads mapped
specifically to the predicted cut site regions. This degree
of specificity is striking, especially considering the high
genetic divergence between different experimental lines
of zebrafish, including differences between our lab strains
and the sequenced reference line that we used to predict
cut sites [31, 32].
Mutation-calling in tumors
RADseq data can be analyzed using standard tools
for alignment to a reference genome and genotyping/
mutation calling [19]. We aligned reads to the zebrafish
(danRer7) reference genome using BWA [33] and
identified mutations with MuTec [34] (see methods). By
comparing melanoma tumor to normal skin for each adult
fish, we were able to identify single nucleotide variants
41793
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(SNVs). The total number of SNVs identified in the three
adult fish tumors were 3, 8, and 5 (Figure 2B). These
numbers are consistent with previous characterization
of engineered zebrafish melanomas from whole exome
sequencing which capture ~3% of the genome and find
low mutational burden on average, with significant
variation among tumors [35].

To demonstrate how the choice of restriction
enzyme influences the number of mutations captured
with RADseq, we used the same genomic DNA from
one of the SbfI-digested fish described above and made
an additional RADseq library using a more frequentlycutting enzyme, NsiI (a 6bp recognition sequence). In
silico analysis predicts 687,595 NsiI cut sites in the

Figure 1: A. Comparison of whole-genome, exome and RADseq approaches to cancer genome. Whereas whole genome sequencing
allows for an unbiased view of the genome, it requires high cost when high sequencing depth is needed. Exome sequencing is a reduced
representation approach that is cost-effective but gives a highly biased view of only protein coding genes, which are under selection in many
cancers. RADseq uses restriction sites naturally dispersed across the genome at both intergenic as well as coding regions, combining the
benefits of whole-genome and exome sequencing to allow for unbiased, high sequencing depth in a highly cost effective manner. B. Specific
features of the 3 methods as they apply to cancer biology.
www.impactjournals.com/oncotarget
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Figure 2: Applying RADseq to a zebrafish model of melanoma. A. A transgenic zebrafish model in which the mitfa promoter

drives human oncogenic BRAFV600E. The embryos (left) and young adults (center) are relatively normal, but all adults (right) develop
clinically overt melanomas within 4-12 months. Genomic DNA was isolated from a melanoma as well as surrounding skin in four of these
transgenic animals and RADseq libraries were created from gDNA using either SbfI (0.4% of the genome) or NsiI (9% of the genome).
B. The efficiency of reads mapping to restriction enzyme cut sites in the genome, along with the depth of coverage and the number of
mutations discovered in each melanoma. We found a small number of mutations in 3 melanomas when sampling 0.4% of the genome.
For one fish, the same genomic DNA was used for RADseq with NsiI, and shows a much higher number of mutations, given the greater
coverage of the genome. C. A fate-mapping transgenic line was created to assess the efficiency of RADseq on subpopulations of cells. The
mitf-BRAF;p53 model was bred with a fluorescent color “switch” line in which a floxed GFP cassette can be swapped for an mCherry
cassette upon Cre-mediated recombination. This cross was injected with a melanocyte-specific mitf-CreERT2 plasmid. Upon endoxifen or
tamoxifen treatment, a subset of the melanocytes in the skin as well as within the melanoma switched from GFP to mCherry. Genomic DNA
was extracted from either the bulk tumor/skin, or from FACS sorted mCherry+ melanocytes from the tumor/skin pair. D. Overall variant
allele fractions across all mutations in the sorted vs. unsorted populations showed a significant increase in the mCherry+ subpopulations
(*,p < 0.05, t-test). E. Individual mutation variant allele fractions are shown, consistently demonstrating increased sensitivity in the sorted
population, which facilitates higher-confidence mutation calling in subclonal populations.
www.impactjournals.com/oncotarget
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zebrafish genome, and again we found our reads mapped
to these regions with an on-target rate greater than 90%.
Sequencing 100bp flanking each side of these cut sites
results in representation of approximately 9% of the
zebrafish genome. As expected, with many more bases
in the genome represented in the NsiI library, the number
of mutations was greater than for the SbfI library - we
detected 47 mutations in NsiI-flanking regions versus the
5 mutations detected in the SbfI-flanking regions of the
same melanoma tumor (Figure 2B and Supplemental Table
1).

lineages typically make up a single biopsy or tissue
sample [36]. In addition, normal cells such as fibroblasts
and immune cells are present within a dissected tumor
sample, at varying frequencies [37]. This means that
typical libraries prepared for tumor sequencing represent
a mixture of cells with different genotypes. Single-cell
sequencing has promise to overcome some of these
challenges, but it remains technically difficult and
expensive to characterize comprehensive mutational
profiles from single cells [38].
We developed a transgenic zebrafish with
an inducible system to selectively trace subsets of
melanocytes both in normal skin as well as within the
melanoma (Figure 2C). We started with an existing
zebrafish line (ubi:Switch) [39, 40] that possesses
a ubi:loxP- GFP-loxP-mCherry cassette. These

Lineage-tracing model to study tumor evolution of
subclonal populations
One of the challenges to studying genetic evolution
in tumors is heterogeneity - multiple subclonal tumor

Figure 3: RADseq can identify somatic mosaicism. A. Multiple normal tissues were extracted from both WT and BRAF;p53
fish, including brain, skin, blood, liver, and spleen. Genomic DNA was isolated and RADseq performed using NsiI. As shown in A., these
tissues represent ontologically distinct origins from the zygote. B. Mutations were detected in the melanoma as expected. In addition, a
somatic mutation was identified and validated in the seemingly-normal brain of the BRAf;p53 fish, an area devoid of BRAF expression.
C. No somatic mutations were detected in any of the tissues derived from the WT animal. D., E. The RADseq library was used to detect
copy number changes in the above tissues. This revealed two significant copy number amplifications on chromosome 6 in the melanoma,
whereas all other tissues from both WT and BRAF;p53 were largely diploid.
www.impactjournals.com/oncotarget
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Figure 4: RADseq is adaptable to human cancer specimens. A. Through a rapid autopsy program, tissues were obtained from a
patient with metastatic pancreatic ductal adenocarcinoma (PDAC). These included three tumor-free normal tissues (lung, spleen, kidney),
the primary pancreatic tumor, and a mesenteric metastasis. Genomic DNA was isolated from these tissues and subject to RADseq using
NsiI. B. We identified 168 mutations in the metastasis and 164 mutations in the primary tumor. C. An example IGV plot showing the same
mutation on chromosome 20 identified by RADseq (top) and whole-genome sequencing (bottom). RADseq shows bidirectional reads
emanating from the cut site, in contrast to the random tiling of reads in the whole-genome approach. D. Mutations in the primary tumor and
metastasis were used to construct a phylogenic tree depicting the evolutionary history among the sequenced populations. 160 mutations are
present in the primary tumor and metastasis, indicating that these mutations were already present in the ancestral population that gave rise
to the two tumors. Four mutations are unique to the primary tumor, and eight mutations are unique to the metastasis, indicating that these
mutations occurred after the two populations diverged.
www.impactjournals.com/oncotarget
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fish ubiquitously express GFP until exposed to Cre
recombinase, which induces a deletion of the GFP coding
region and expression of mCherry. We crossed these
zebrafish with the (p53-/-; mitfa-BRAFV600E +/+) zebrafish
line that spontaneously develops melanoma. Into this
background, we injected an inducible Cre transgene
(mitfa:CreERt2-SV40) under the control of the mitfa
melanocyte-specific promoter [41]. Exposure to the drug
Tamoxifen induces Cre-mediated excision of the GFPlox complex in melanocytes specifically, causing those
cells to express mCherry, while the rest of the somatic
cells continue to express GFP. We screened for fish that
successfully integrated the transgene into their germline
and whose offspring show a strong and specific switching
of GFP to mCherry expression in melanocytes. The
result is a stable line of melanoma-prone zebrafish with
inducible fluorophore-based lineage tracing in melanocyte
lineages. These fish can be treated with tamoxifen as
embryos or adults to induce an irreversible color change in
melanocytes. After the drug is removed, the labeled cells
continue to express mCherry, and they pass this change on
to their daughter cells, resulting in labeled clonal lineages
that can be separated from other cells using FACS.
We found that the RADseq method can be used to
identify mutations in sorted tumor populations from these
animals. We applied tamoxifen to fish with melanoma
tumors to label melanocytes in tumors and normal skin
before dissection. We dissected tissue, disassociated cells,
and used FACS to separate the mCherry+ melanocytes
from contaminating stromal cells, and prepared the cells
for downstream sequence analysis. We also reserved a
portion of each dissected tissue for traditional RADseq
analysis of the unsorted population. Nine mutations
were identified in both the sorted and unsorted analyses.
These mutations show a significantly higher frequency
in the sorted (M = 30.56) than the unsorted (M = 25.67)
population; t(8) = 7.72, p < .0001 (Figure 2D/E and
Supplemental Table 2) which is consistent with the
expectation that the specific sorting of melanocytes
allowed us to reduce the number of contaminating
normal cells in the sample. We believe this system will
provide a powerful system to isolate and study subclonal
populations of normal and tumor melanocytes throughout
development.

of skin, blood, and liver was based on the fact that these
tissues are derived from different developmental germ
layers (ectoderm, mesoderm, and endoderm, respectively)
and therefore form distinct lineages early in embryonic
development and have the most potential to acquire
distinct somatic changes (Figure 3A). The brain is derived
from the ectoderm along with skin, and we included this
additional tissue because acquired somatic mosaicism
has been previously described in this organ [42-45]. We
used SbfI to RAD-sequence each of these tissues (see
Supplemental Table 3 for RADseq metrics), and detected
a somatic mutation specific to the brain sample of the
transgenic fish (i.e. a polymorphism present in the brain
tissue, but not in the liver, skin, or melanoma tumor from
that same animal) (Figure 3B). We confirmed the presence
of this mutation in the brain (and absence in other tissues)
through targeted PCR of the original genomic DNA and
additional deep sequencing of the PCR amplicons to
~1000x coverage in a subsequent HiSeq run. The mutation
has a frequency of over 20% in the brain, which indicates
that the mutation likely occurred early in development. We
did not detect derived mutations in any tissues of the wildtype fish (Figure 3C).
Assessing copy number alterations with RADseq
RADseq has been previously shown to be an
effective tool to identify copy number alterations in
human tumors [46]. To our knowledge, this study by
Zheng et al. is the only previous application of the
RADseq method to cancer. We analyzed the SbfI-digested
RADseq samples from normal and melanoma tissue
from melanoma-prone and wild-type fish for evidence
of copy number alterations. We identified two regions
of chromosome six in the melanoma tumor sample that
show strong evidence of amplification (Figure 3D). These
regions contain 116 genes, and are not among previouslydocumented recurrently amplified regions in engineered
zebrafish melanomas [35]. Although we cannot evaluate
the functional importance of copy number alterations
from sequence data alone, the amplified regions do
contain several genes of interest including the zebrafish
ortholog of the human transcription factor, Myc, which
is a frequently mutated oncogene in humans including
amplification/overexpression in 6% of melanomas in the
TCGA database [47, 48].
We did not detect any copy number changes in
any of the normal tissues of the melanoma-prone fish
or the wild-type fish (Figure 3E). RADseq has specific
advantages for studies of copy number alterations because
the selection of restriction enzyme sets the resolution at
which copy number change events can be detected. A
frequently-cutting enzyme will produce a high density of
markers throughout the genome to identify amplifications
and deletions of small genomic regions. A rare cutter
will produce a lower density of markers spread across
the genome, and can be used to identify amplifications

Capturing somatic mosaicism with RADseq
We dissected and sequenced different tissues from
a melanoma-prone zebrafish and a wild-type zebrafish
to test whether acquired genetic variation could be also
be detected in somatic lineages other than the tumor
population, given that the fish were p53 deficient in all
tissues. To do so, we dissected two additional normal
tissues, brain and liver, to supplement the skin and
melanoma samples from one of the transgenic fish
described above. We also isolated brain, skin, blood and
liver samples from a wild-type zebrafish. Our selection
www.impactjournals.com/oncotarget
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and deletions of large genomic regions, with very low
sequencing cost.

of these same samples [49-51]. Although RADseq is not
an efficient method to search for driver genes in cancer,
there happens by chance to be an NsiI cut site adjacent to
this important region, thus cut sites adjacent to hot spots
can also identify somatic variants of importance.
To compare results between RADseq and WGS, we
independently analyzed sequence data from the wholegenome sequence library. All reads were aligned against
the human reference genome, and we used MuTect to
identify single nucleotide variants. For efficiency, we
restricted mutation calling to regions of the genome
adjacent to NsiI cut sites. The whole-genome sequence
libraries confirmed the presence of 100% of the RADseqdetected variants.
We used mutation information from primary tumor
and metastasis to infer a phylogenetic tree that depicts
the evolutionary history underlying tumor progression
(Figure 4D). 160 mutations occur before the primary
tumor and metastasis lineages diverge. 8 mutations occur
along the metastasis lineage, and 4 mutations occur in the
primary tumor lineage after its split from the metastasis
lineage. These results are consistent with previous studies
of pancreatic cancer patients that show a long history of
shared mutations among primary tumors and metastases,
with fewer unique mutations distinguishing individual
tumors within patients [11].

Human pancreatic cancer samples from primary
and metastatic sites
A unique feature of RADseq is that the same
protocol and reagents can be used for any species because
there are no sequence-specific capture steps (e.g. exonic
baits) involved. We used the enzyme NsiI to generate
RADseq libraries for tissue samples obtained from a
human pancreatic cancer patient through a rapid autopsy
program (Figure 4A) [11]. In silico analysis using the
human reference genome hg19 predicts 922,636 NsiI
cut sites in the genome. Sequencing 100bp flanking
both directions of each cut site results in representation
of approximately 6% of the human genome. Note that
this is a larger fraction of genome coverage than is
targeted by common exome capture kits which typically
represent approximately 50-65Mb (~2% of the human
genome). Similar to performance in zebrafish described
above, RADseq showed very high efficiency with the
NsiI enzyme in human tissues (see Supplemental Table
4 for RADseq metrics). After filtering for quality, 92.4%
of reads successfully mapped to the human reference
genome. 97.0% of these reads mapped to the predicted
cut site regions, and 99.28% of predicted cut site regions
received sequence coverage. The average depth of
coverage was ~50x (52x mean, 49.6x median).
The tissues included in this study were primary
pancreatic tumor, mesentery metastasis, and normal
spleen. These tissues had already undergone wholegenome sequencing (WGS), and thus provided an
independent and comprehensive sequence dataset that we
could use to validate RADseq performance for identifying
mutations. After filtering for quality, we aligned reads
to the reference genome using BWA, and we called
mutations with MuTect. We identified 168 mutations
distinguishing the metastasis from the normal sample
and 164 mutations distinguishing the primary tumor
from the normal sample (Figure 4B and Supplemental
Table 5 for a list of all mutations detected). 116 (67%)
of the 172 total unique mutations that we detected fall in
intergenic regions, 53 (31%) are in introns, and 3(2%)
are in exons (an example of which is shown in Figure
4C). This distribution is consistent with the composition
of the human genome, and supports the prediction that
RADseq loci are distributed approximately randomly in
the genome and that the majority of mutations detected
will be functionally neutral. Of the three exonic mutations,
one was silent and two were missense mutations, in codon
12 of KRAS and exon 49 of FBN1. The mutation that we
detected in codon 12 of KRAS (G12D) is a common and
important driver in pancreatic and other cancers and is
concordant with that found by whole genome sequencing
www.impactjournals.com/oncotarget

DISCUSSION
When applied to the appropriate research questions,
RADSeq provides an efficient, flexible and cost effective
method to utilize the power of next-generation sequencing
technologies to gain new insights into the ecological and
evolutionary dynamics of cancer. Some additional details
regarding study design and analysis will be useful for
cancer biologists employing this technique.
Study design: When designing a RADseq
experiment, the choice of restriction enzyme will
determine the number of loci represented in each sequence
library. It is important to have an expectation for the
number of cut sites produced by potential restriction
enzymes in order to design an experiment that will provide
sufficient genetic resolution for the research question, and
to anticipate how much sequencing will be required to
achieve a given depth of coverage per site. The simplest
estimate is that an 8-cutter will cut every 48 = 65,536bp
and a 6-cutter will cut every 46 = 4,096bp, but many
genomes and enzymes will deviate significantly from
this expectation [19]. The calculation can be improved by
accounting for the GC content of the cut site and genome
under study, however, the most accurate estimates for
numbers of cut sites can be obtained through in silico
analysis from a published reference genome for the
species under study. Computational tools exist to help
plan an appropriate sequencing effort for a given target
depth by estimating the number of loci expected for a
41799
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given protocol and genome [52]. The number of bases
represented per genome will also be determined by the
read length of the sequencing technology (typically up to
150bp reads currently with Illumina, for example). Most
questions can be sufficiently addressed with short reads
and single-end sequencing, but longer reads can also be
obtained by assembling contigs from paired-end sequence
reads.
Quality and quantity of starting material: RADseq
library preparation protocols have been optimized for
high-molecular weight genomic DNA, and are not
expected to perform as well with highly degraded DNA
such as that obtained from FFPE tissue [53]. In degraded
samples, small fragments of starting DNA not adjacent to
cut sites may end up in the sequencing library and waste
sequencing effort on off-target loci. Also, the mechanical
shearing step to produce fragments of optimal size for
the sequencing platform works best with relatively large
fragments present after enzyme digestion. In addition
to high quality DNA, a large quantity of starting DNA
is beneficial because it can reduce the number of PCR
cycles required for the final step of library prep to reduce
PCR bias/duplicates. Early RADseq papers recommend
as much as 1ug of starting DNA, but more recent studies
have shown successful library prep with as little as 50100ng DNA per sample [19].
Error: RADseq is subject to many of the same
sources of error that challenge all high-throughput
sequencing studies of cancer genomics. Type II error or
‘false negative’ mutation calls can occur if a mutation
is present at low frequency within the tumor population
and sequencing depth is insufficient to resolve the
variant. RADseq may be less susceptible to this type of
false negative than whole exome sequencing or whole
genome sequencing because the cost-effectiveness of
RADSeq enables greater sequencing depth per site. False
negative mutation calls can also occur when tumors
contain genetic heterogeneity that is not captured in a
single biopsy. RADseq again may have advantages over
WES and WGS with regards to this problem because the
more cost-effective approach enables the sequencing of
multiple spatially-independent tumor samples (multiregion sequencing) instead of a single biopsy. Type I
error or ‘false positive’ mutation calls also need to be
considered in all high-throughput sequencing studies of
tumors. False positives due to mapping errors of reads to
the reference genome can be minimized in RADseq with
the same bioinformatics preprocessing tools designed
to address these problems in whole genome and whole
exome studies, such as GATK indel realignment [54].
We find that mapping errors are easier to identify with
RADseq than other sequencing methods because the
palindromic nature of the restriction enzyme cut sites
should result in two sets of reads independently mapping
to the same genomic region - one from each direction of
the cut site. False positive mutation calls can also result
www.impactjournals.com/oncotarget

from PCR errors occurring during the library preparation.
These errors need to be addressed differently in RADseq
than whole genome or whole exome studies, as we discuss
in detail below.
PCR errors and duplicates: Like most nextgeneration sequencing library preparation protocols,
RADseq methods include a PCR step to enrich for
fragments that have successfully ligated sequencing
adapters. This amplification can potentially lead to
erroneous downstream mutation calls, if duplicates that
contain PCR errors appear as mutations. The standard
method to eliminate PCR duplicates from whole-genome
and whole-exome sequence libraries involves removing
reads that start and end at the exact same genomic position.
This method is not appropriate for RADseq libraries
because reads consistently begin at the restriction enzyme
cut site. To eliminate PCR duplicates from RADseq data,
several alternative methods are available. One option is to
use paired-end sequencing (i.e. sequence the randomlysheared end of the DNA as well as the cut-site end, to
remove reads with identical start and end positions).
Alternatively, parallel PCR reactions can be performed
for each sample and sequenced in separate lanes. Our
preferred method is to use multiple barcodes for each
individual sample (introduced as a mixture during library
prep) and ensure that mutations identified at a particular
locus are confirmed by reads containing different barcodes
(and thus not the result of PCR error and duplication). The
use of multiple barcodes also increases the complexity
of the library, which leads to better cluster identification
on the Illumina platform. A final way to eliminate PCR
duplicates is to eliminate the PCR step of library prep
altogether, but this requires higher starting quantities of
genomic DNA.
Reagents: The RADseq protocol requires an initial
financial investment in specialized barcoded adapters,
but adapter sequences are non-proprietary and a single
set of oligonucleotides is sufficient for a large number of
libraries. Additionally, the same set of adapters can be used
for compatible sets of enzymes that leave the same sticky
end. For example, the two enzymes used in this study
(SbfI and NsiI) leave the same ACGT overhang, so we
were able to use a single set of adapter oligos to produce
libraries from both restriction enzymes. The same set of
barcoded adapter oligos can also be used for different
species, as we demonstrate with human and zebrafish.

CONCLUSIONS
Many studies of evolution in cancer are more
limited by the number of individuals or tissues sampled
than by the density of markers in the genome, and for
these studies RADseq will be an especially useful tool.
Like other reduced-representation approaches, RADseq
provides advantages over whole genome sequencing, such
as greater depth of coverage per locus and the sequencing
41800
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of higher numbers of samples for a given budget. RADseq
also offers an alternative to whole-exome sequencing
because it captures more neutrally-evolving sites and
thus produces more reliable markers to measure intrinsic
mutation rates and to infer phylogenetic relationships than
sites under strong positive or purifying selection. Our
results demonstrate that RADseq can be an effective tool
to identify single-nucleotide variants and copy number
alterations in humans and animal models. Our detection
of somatic changes in normal tissue of adult zebrafish also
indicates that RADseq can be useful for studies of somatic
mosaicism in development. The transgenic zebrafish
that we created can also be used with RADseq to detect
mutations in subclonal lineages.

combined proportionately for multiplexed sequencing.
Four different barcodes were used for each sample to
increase library complexity and assist in eliminating PCR
errors in downstream processing.

Human tissue dissection and library prep
Tissue sample processing. The patient and tissues
were collected through the Johns Hopkins Gastrointestinal
Cancer Rapid Medical Donation program [58]. Informed
consent was obtained. Upon opening the body cavity,
the entire primary tumor and remaining normal pancreas
were dissected along with each metastasis. All tumor and
normal tissues were flash-frozen in liquid nitrogen and
stored at -80oC. The primary tumor was sliced (0.5 cm
thick) and sectioned into 1x1 cm samples as described
previously [11]. Macrodissection of each metastasis
removed non-neoplastic tissue.
Genomic DNA extraction and quantification.
A phenol and chloroform method was used to
extract genomic DNA (gDNA) from each tumor
sample followed by LINE assay quantification (i.e.
counting long interspersed elements (LINE) using
real-time PCR). The LINE forward primer used was
5’-AAAGCCGCTCAACTACATGG-3’ and the reverse
primer was 5’-TGCTTTGAATGCGTCCCAGAG-3’.
The PCR protocol implemented was 50°C for 2 min, 95°C
for 2 min, 40 cycles of 94°C for 10 s, 58°C for 15 s, and
70°C for 30 s, 95°C for 15 s, and 60°C for 30 s. All PCR
reactions used Platinum SYBR Green qPCR mastermix
(Invitrogen).
Whole genome sequencing and alignment.
Sequencing libraries were prepared using standard
methods for each gDNA sample. Whole genome
sequencing (WGS) utilized an Illumina Hi-Seq 2000
platform for 60x target coverage. Sequencing reads were
aligned to the hg19 human reference genome.

EXPERIMENTAL PROCEDURES
Animal husbandry
All zebrafish were housed in a temperature (28.5C)
and light-controlled (14h on, 10h off) room. Fish were
housed at a density of 5 fish per liter, and fed 3 times
per day using brine shrimp and pelleted zebrafish food.
All procedures adhered to IACUC protocol #12-05-008
through Memorial Sloan Kettering Cancer Center, as
described previously [55].

Zebrafish tissue dissection and DNA extraction
Adult zebrafish were anesthetized in 0.2% Tricaine
and then euthanized by incubation in ice water for 15
minutes. Tissues were dissected according to the protocol
and video published at http://www.jove.com/video/1717/
[56]. Blood was collected according to the protocol and
video published at http://www.jove.com/video/3865/ [57].
DNA was extracted from dissected tumors and normal
tissue using the DNeasy Blood & Tissue Kit (Qiagen),
with an RNAse A treatment step.

Transgenic zebrafish generation
Melanoma-prone
zebrafish
Tg(mitfa:BRAF(V600E)); p53-/- [28] were crossed with the
ubi;Switch zebrafish line (ubi:loxP- GFP-loxP-mCherry)
[39]. A plasmid containing mitf:CreERt2;SV40 was created
in the pDestTol2CG2 destination vector with the Gateway
system [59]. This plasmid (25ng/μl) was injected at
the single cell stage using a micropipette along with
Tol2 RNA (20ng/μl) according to previously described
protocols [39, 60]. Embryos were treated with 20μm
4-OHT (Sigma) at 50% epiboly. At 24 hours, the drug
was refreshed and 0.003% of 1-phenyl-2-thiourea (PTU)
was applied to temporarily block pigment production in
melanocytes and aid in the visualization of fluorophores
[61]. Larvae were imaged at 3dpf to look for color change
in melanocytes from GFP to mCherry. Fish that showed

Library preparation
RADseq libraries were prepared from extracted
DNA according to the method described by Etter et al [22,
23] using the enzymes SbfI-HF and NsiI (New England
Biolabs), with 1μg of DNA starting material. The shearing
step was performed on a Bioruptor+ sonication device
(Diagenode) with 10 cycles of 30 seconds on, 1 minute
off (high setting). Zymo DNA Clean and Concentrator kits
(Zymo Research) were used for each clean-up step. The
final PCR amplifications were run for 12 cycles. We did
not pool samples after the P1 ligation — all samples were
barcoded and processed separately until final quantification
with a Qubit fluorometer (Thermo Scientific) before being
www.impactjournals.com/oncotarget
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strong and specific switching were grown up and then incrossed to produce an F2 population that was also treated
and imaged to confirm incorporation of the transgene in
the germline. These fish were grown up and genotyped
to select for individuals that carry both homozygous
mutations required for the development of melanoma as
well as demonstrating the strong and specific switching
of melanocytes from GFP to mCherry after tamoxifen
treatment. These fish were used to generate a stable line
and for the sequencing in this study.

genomes using BWA [33]. Mutation calling. Mutationcalling was done using MuTect [34]. Manual curation.
The mutation lists generated by MuTect were curated
via manual inspection of the alignment files at each
location using the Integrative Genomics Viewer (IGV)
[66]. Mutations in regions with problematic mapping or
asymmetrical coverage of RADseq reads on each side of
the cut site were omitted.

Copy-number alteration

Tissue digestion and FACS sorting

Restriction sites were located in the zebrafish
genome (danRer7 assembly) via in silico digestion of
SbfI. Only reads that perfectly matched the location of
restriction sites were retained to calculate the coverage
of the sites. To depress the fluctuation of read depth,
we merged 5 consecutive restriction sites as a unit, and
walked along the chromosome via a sliding-window
to calculate average count read number in each unit.
The read depth ratio for each unit of the tested sample
was calculated by dividing corresponding value in liver
sample of melanoma-prone strain or wild-type strain
after normalization of total reads counts. The R package
“DNAcopy” was used to segment the chromosome via
read depth ratio of each tested sample. To resolve the
hyper-segmentation, the FastCall algorithm [67] was
used to merge neighboring segments with similar copy
numbers.

Adult fish were dissected as described above and the
excised tissue was placed in an Eppendorf tube containing
500 μL liberase diluted in DMEM media without serum
(final: 0.15U/ml). A mini pestle was used to mechanically
dissociate the cells. Tubes were then incubated at 37°C
until the cells appeared to be completely dissociated in
the solution. 500 μL of DMEM10 media (with serum)
was added to stop the liberase activity. The cells were
then pelleted by centrifugation at 500 RCF for 5 min in a
refrigerated centrifuge. The supernatant was discarded and
cells resuspended in PBS buffer. The solution was filtered
into a FACS tube through a 40 μm mesh filter, with Dapi
(1:100). mCherry positive cells were separated from GFP
positive cells on an Aria III FACS machine with gating set
by controls from pure populations of zebrafish in vitro cell
lines. DNA was extracted from sorted cells as described
above.
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